White RA - Search Results

1

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW; IFNB Multiple Sclerosis Study Group. Petkau AJ, et al. Among authors: white ra. Mult Scler. 2004 Apr;10(2):126-38. doi: 10.1191/1352458504ms1004oa. Mult Scler. 2004. PMID: 15124756

2

Statistical approaches to assessing the effects of neutralizing antibodies: IFNbeta-1b in the pivotal trial of relapsing-remitting multiple sclerosis.

Petkau AJ, White R. Petkau AJ, et al. Neurology. 2003 Nov 11;61(9 Suppl 5):S35-7. doi: 10.1212/01.wnl.0000092364.87561.f1. Neurology. 2003. PMID: 14610111

3

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. Kastrukoff LF, et al. Neurology. 1999 Jan 15;52(2):351-9. doi: 10.1212/wnl.52.2.351. Neurology. 1999. PMID: 9932956 Clinical Trial.

4

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.

Petkau J, White R. Petkau J, et al. Mult Scler. 1997 Dec;3(6):402. doi: 10.1177/135245859700300610. Mult Scler. 1997. PMID: 9493643 No abstract available.

5

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. Kastrukoff LF, et al. J Neuroimmunol. 1998 Jun 15;86(2):123-33. doi: 10.1016/s0165-5728(98)00014-9. J Neuroimmunol. 1998. PMID: 9663557

6

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group. Goodin DS, et al. Mult Scler. 2012 Feb;18(2):181-95. doi: 10.1177/1352458511418629. Epub 2011 Sep 27. Mult Scler. 2012. PMID: 21952094 Clinical Trial.

7

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.

Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.

8

Longitudinal analyses for magnetic resonance imaging outcomes in multiple sclerosis clinical trials.

D'yachkova Y, Petkau J, White R. D'yachkova Y, et al. J Biopharm Stat. 1997 Nov;7(4):501-31. doi: 10.1080/10543409708835204. J Biopharm Stat. 1997. PMID: 9358326 Review.

9

Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging.

Reich DS, White R, Cortese IC, Vuolo L, Shea CD, Collins TL, Petkau J. Reich DS, et al. Mult Scler. 2015 Nov;21(13):1693-704. doi: 10.1177/1352458515569098. Epub 2015 Feb 6. Mult Scler. 2015. PMID: 25662351 Free PMC article. Clinical Trial.

10

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.

Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D; European Study Group in Interferon Beta-1b in Secondary Progressive MS. Polman C, et al. Neurology. 2003 Jan 14;60(1):37-43. doi: 10.1212/wnl.60.1.37. Neurology. 2003. PMID: 12525715 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

753 results

Search Page